| Literature DB >> 29201864 |
Alessandra Prosperini1, Houda Berrada1, María José Ruiz1, Francesca Caloni2, Teresa Coccini3, Leon J Spicer4, Maria Chiara Perego4, Alessandra Lafranconi5,6.
Abstract
Mycotoxin enniatin B (ENN B) is a secondary metabolism product by Fusarium fungi. It is a well-known antibacterial, antihelmintic, antifungal, herbicidal, and insecticidal compound. It has been found as a contaminant in several food commodities, particularly in cereal grains, co-occurring also with other mycotoxins. The primary mechanism of action of ENN B is mainly due to its ionophoric characteristics, but the exact mechanism is still unclear. In the last two decades, it has been a topic of great interest since its potent mammalian cytotoxic activity was demonstrated in several mammalian cell lines. Moreover, the co-exposure in vitro with other mycotoxins enhances its toxic potential through synergic effects, depending on the concentrations tested. Despite its clear cytotoxic effect, European Food Safety Authority stated that acute exposure to ENNs, such as ENN B, does not indicate concern for human health, but a concern might be the chronic exposure. However, given the lack of relevant toxicity data, no firm conclusion could be drawn and a risk assessment was not possible. In fact, very few studies have been carried out in vivo and, in these studies, no adverse effects were observed. So, research on toxicological effects induced by ENN B is still on-going. Recently, some studies are dealing with new advances regarding ENN B. This review summarizes the information on biochemical and biological activity of ENN B, focusing on toxicological aspects and on the latest advances in research on ENN B.Entities:
Keywords: biochemical activities; biological properties; emerging findings; enniatin B; toxic effects
Year: 2017 PMID: 29201864 PMCID: PMC5697211 DOI: 10.3389/fpubh.2017.00304
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Figure 1Chemical structure of enniatins (ENNs).
Figure 2Scheme of the ionophore enniatin (ENN) B carrying ions by diffusing through membrane lipids.
In vivo toxicity studies of enniatin B (ENN B).
| Animal | Dosage/route | Effects | Reference |
|---|---|---|---|
| Broiler chicken | 0.2 mg/kg b.w. | Tissue bioaccumulation | Fraeyman et al. ( |
| Bolus | |||
| Mice | 5 mg/kg b.w.of ENN B | No acute damage | Rodríguez-Carrasco et al. ( |
| Intraperitoneal on two consecutive days | Tissue bioaccumulation | ||
| Mice | 1.25–40 mg/kg b.w. (every 8 h) | Mice died in 2–5 days (10–40 mg/kg b.w.) | McKee et al. ( |
| Intraperitoneal | Reduction of weight | ||
| No anti-HIV activity | |||
| Pigs | 0.05 mg/kg b.w. | Absorption | Devreese et al. ( |
| Oral bolus | ENN B > B1 > A1 > A | ||
| Wistar rats | Mixture of ENNs containing 1.19, 2.16, 1.03 and 1.41 mg/kg b.w.of ENN A, A1, B, and B1 | No adverse effect | Escrivá et al. ( |
| Oral | |||
Figure 3Schema showing in vitro effects of enniatin B (ENN B).
In vitro cytotoxicity studies on enniatin B determined by different toxicity endpoint, time of exposure and cell types.
| Cell lines | Cell types | Parameter | Exposure time (h) | IC50 (μM) | Reference |
|---|---|---|---|---|---|
| A427 | Human lung cancer | MTT | 72 | ENNmix: 1.61 ± 0.14 | Dornetshuber et al. ( |
| A549 | ENNmix: 4.08 ± 1.04 | ||||
| Balb 3T3 | Mouse embryo fibroblast | ATP production | 24 | ED50: 8.4 ± 0.76 | Jonsson et al. ( |
| BrdU ELISA | ED50: 4.24 ± 0.06 | ||||
| Apoptosis induction | ED50: 11 | ||||
| Caco-2 | Human colon adenocarcinoma | NR | 3, 24 | 10.0 ± 3.8–2.1 ± 0.4 | Ivanova et al. ( |
| 24, 48, 72 | >15–1.4 ± 0.2 | Prosperini et al. ( | |||
| 24, 48 | >30 | Meca et al. ( | |||
| 24, 48 | No IC50 value obtained | Meca et al. ( | |||
| 72 | ENNmix: 1.99 ± 0.09 | Dornetshuber et al. ( | |||
| 24, 48, 72 | >15–11.7 ± 2.4 | Prosperini et al. ( | |||
| WST-1 | 24 | 6.3 | Vejdovszky et al. ( | ||
| CHO-K1 | Chinese hamster ovary | MTT | 24, 48, 72 | 11.0 ± 2.65–2.80 ± 0.16 | Lu et al. ( |
| 24 | 11.0 ± 2.65 | Lombardi et al. ( | |||
| C6 | Rat glioma | MTT | 3, 24 | ENNmix: 2.5–10 | Wätjen et al. ( |
| GLC-4 | Breast adenocarcinoma | MTT | 72 | ENNmix: 2.40 ± 1.53 | Dornetshuber et al. ( |
| GLC-4/adr | MVP-overexpressing subline | MTT | 72 | ENNmix: 1.41 ± 0.83 | Dornetshuber et al. ( |
| GBL1 | Human Glioblastoma | MTT | 72 | ENNmix: 2.65 ± 0.30 | Dornetshuber et al. ( |
| GBL2 | ENNmix: 2.29 ± 0.05 | ||||
| GBL3 | ENNmix: 2.55 ± 0.14 | ||||
| GBL4 | ENNmix: 2.33 ± 0.30 | ||||
| H-4IIE | Rat hepatocarcinoma | MTT | 3, 24 | ENN A1, B and B1: 1–1.5 | Wätjen et al. ( |
| Hep G2 | Human hepatocarcinoma | MTT | 24, 48 | No IC50 value obtained | Meca et al. ( |
| 3, 24 | ENN A1, B and B1: 10 | Wätjen et al. ( | |||
| Alamar Blue BrdU | 24 | 206.7–435.9 | Ivanova et al. ( | ||
| ATP production | 24 | ED50: 2.9 ± 0.7 | Jonsson et al. ( | ||
| BrdU ELISA | ED50: 0.50 ± 0.09 | ||||
| Qaudroprobe multiparametric liver toxicity assay | 24, 72 | 0.9 | Svingen et al. ( | ||
| HL60 | Promyelocityc leukemia carcinoma | MTT | 72 | ENNmix: 1.74 ± 0.20 | Dornetshuber et al. ( |
| HL60/vinc | ABCB1-overexpressing subline | MTT | 72 | ENNmix: 2.40 ± 0.14 | Dornetshuber et al. ( |
| HL60/adr | ABCC1-overexpressing subline | MTT | 72 | ENNmix: 2.1 ± 0.12 | Dornetshuber et al. ( |
| HT-29 | Human colon adenocarcinoma | MTT | 24, 48 | 2.8 ± 0.9 | Meca et al. ( |
| HUVEC | Human endothelial | MTT | 72 | ENNmix: 7.89 ± 0.21 | Dornetshuber et al. ( |
| KB-3-1 | Epidermal carcinoma | MTT | 72 | ENNmix: 1.95–0.12 | Dornetshuber et al. ( |
| KBC-1 | ABCB1-overexpressing subline | MTT | 72 | ENNmix: 1.77 ± 0.04 | Dornetshuber et al. ( |
| MDA-MB-231 | Alveolar epithelial | MTT | 72 | ENNmix: 2.36 ± 1.57 | Dornetshuber et al. ( |
| MDA-MB-231/adr | ABCG2-overexpressing subline | MTT | 72 | ENNmix: 3.18 ± 1.70 | Dornetshuber et al. ( |
| MGC | Human glioblastoma | MTT | 72 | ENNmix: 3.04 ± 0.58 | Dornetshuber et al. ( |
| MRC-5 | Fibroblast-like fetal lung | Alamar Blue BrdU | 24 | 1.9–9.8 | Ivanova et al. ( |
| 1.9–3.6 | |||||
| OS 9 | Human osteosarcoma | MTT | 72 | ENNmix: 3.55 ± 0.77 | Dornetshuber et al. ( |
| OS 10 | ENNmix: 2.10 ± 0.15 | ||||
| Porcine kidney cells-15 | Porcine Kidney | MTT | 72 | ENNmix: 41 | Uhlig et al. ( |
| RAW 264.7 | Murine macrophage | Alamar blue | 24 | 2.6 | Gammelsrud et al. ( |
| NR | 4.7 | ||||
| SAOS | Human osteosarcoma | MTT | 72 | ENNmix: 2.13 ± 0.07 | Dornetshuber et al. ( |
| SW1537 | Small cell lung carcinoma | MTT | 72 | ENNmix: 2.16 ± 0.12 | Dornetshuber et al. ( |
| SW1537/2R160 | ABCB1-overexpressing subline | MTT | 72 | ENNmix: 2.69 ± 0.60 | Dornetshuber et al. ( |
| SW480 | Small cell lung carcinoma | MTT | 72 | ENNmix: 4.00 ± 1.12 | Dornetshuber et al. ( |
| T98-G | Human glioblastoma | MTT | 72 | ENNmix: >10 | Dornetshuber et al. ( |
| U373 | Human glioblastoma | MTT | 72 | ENNmix: 4.88 ± 0.09 | Dornetshuber et al. ( |
| U2-OS | Osteosarcoma | MTT | 72 | ENNmix: 1.77 ± 0.24 | Dornetshuber et al. ( |
| V79 | Chinese hamster fibroblast | NR | 48 | 4.4 | Dornetshuber et al. ( |
| Alamar blue | 24–48 | 34 ± 20–2.5 ± 0.4 | Föllmann et al. ( | ||
| NR | 36 ± 16–4 ± 1.5 | ||||
| Protein content (BCA) | |||||
| VM8 | Melanoma | MTT | 72 | ENNmix: 3.19 ± 0.85 | Dornetshuber et al. ( |
| VM18 | ENNmix: 2.67 ± 0.08 | ||||
| VM22 | ENNmix: 1.75 ± 0.15 | ||||
| VM33 | ENNmix: 9.65 ± 0.13 | ||||
| VM25 | ENNmix: 2.72 ± 0.11 | ||||
| VL8 | Human lung cancer | MTT | 72 | ENNmix: >10 | Dornetshuber et al. ( |
| WI-38 | Embryonic fibroblast | MTT | 72 | ENNmix: >10 | Dornetshuber et al. ( |
IC.
.
.
Combinedeffect of ENN B tested in combination with other mycotoxins by in vitro methods.
| Cell line | Mycotoxin combination | Effect | Interaction (in the combination) | Reference |
|---|---|---|---|---|
| Caco-2 | ENN A + A1 | Cytotoxicity | Add | Prosperini et al. ( |
| ENN A + B | ||||
| ENN A + B1 | ||||
| ENN B + B1 | ||||
| ENN A + A1 + B1 | ||||
| ENN A + B + B1 | ||||
| ENN A1 + B + B1 | ||||
| ENN A + A1 + B + B1 | ||||
| ENN A1 + B1 | Syn | |||
| ENN A1 + B | ||||
| ENN A + A1 + B | ||||
| ENN B + B1 | Ant | |||
| ENN B + ZEA | Cytotoxicity | Ant | Vejdovszky et al. ( | |
| ENN B + DON | ||||
| ENN B + NIV | Strong | |||
| Antagonism | ||||
| ENN B + AOH | Syn | Fernandez-Blanco et al. ( | ||
| ENN B + DON | Add/Syn | |||
| ENN B + AOH + DON | Add/Syn | |||
| CHO-K1 | ENN A + B1 | Cytotoxicity | Add | Lu et al. ( |
| ENN A1 + B | ||||
| ENN B + B1 | ||||
| ENN A + A1 | Syn | |||
| ENN A + B | ||||
| ENN A1 + B1 | ||||
| ENN A + A1 + B | ||||
| ENN A + B + B1 | ||||
| ENN A + A1 + B1 | Ant | |||
| ENN A1 + B + B1 | ||||
| Human hematopoietic progenitors | BEA + ENN B | Myelotoxicity | Add | Ficheux et al. ( |
AOH, alternariol; DON, deoxynivalenol; ZEA, zearalenone; NIV, nivalenol; ENN, Enniatin.